Idiotype vaccines for lymphoma therapy

References

• Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene29(16), 2309–2324 (2010).
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer10(8), 550–560 (2010).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer9(9), 675–681 (2009).
   PubMed Web of Science ®Google Scholar
• Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat. Rev. Drug Discov.9(7), 513–514 (2010).
   PubMed Web of Science ®Google Scholar
• Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J. Natl Cancer Inst.102(15), 1108–1110 (2010).
   PubMedGoogle Scholar
• Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther.1(1), 65–72 (2001).
   PubMedGoogle Scholar
• McCarty H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br. J. Haematol.123(5), 770–781 (2003).
   PubMed Web of Science ®Google Scholar
• Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev. Vaccines3(2), 163–170 (2004).
   PubMedGoogle Scholar
• Bendandi M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia14(8), 1333–1339 (2000).
   PubMed Web of Science ®Google Scholar
• Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J. Clin. Invest.113(10), 1498–1510 (2004).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med.327(17), 1209–1215 (1992).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Inogés S, Rodríguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst.98(18), 1292–1301 (2006).
   PubMed Web of Science ®Google Scholar
• López-Díaz de Cerio A, Inogés S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines8(1), 43–50 (2009).
   PubMedGoogle Scholar
• Bendandi M, Marillonnet S, Kandzia R et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann. Oncol.21(12), 2420–2427 (2010).
   PubMed Web of Science ®Google Scholar
• Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods89(1), 61–72 (1986).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M. Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit. Rev. Oncol. Hematol.52(1), 1–7 (2004).
   PubMed Web of Science ®Google Scholar
• Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica88(12), 1438–1440 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood89(9), 3129–3135 (1997).
   PubMed Web of Science ®Google Scholar
• Nelson EL, Li X, Hsu FJ et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin’s lymphoma. Blood88(2), 580–589 (1996).
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev.23(3), 137–142 (2009).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood99(5), 1517–1526 (2002).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol.22(23), 4717–4724 (2004).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood109(3), 951–953 (2007).
   PubMed Web of Science ®Google Scholar
• Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood113(23), 5743–5746 (2009).
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. Idiotype vaccination for lymphoma: moving towards optimisation. Leuk. Lymphoma50(1), 1–2 (2009).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA93(20), 10972–10977 (1996).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet345(8956), 1016–1020 (1995).
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood96(8), 2828–2833 (2000).
   PubMed Web of Science ®Google Scholar
• Kannan S, Neelapu SS. Vaccination strategies in follicular lymphoma. Curr. Hematol. Malig. Rep.4(4), 189–195 (2009).
   PubMedGoogle Scholar
• Barrios Y, Cabrera R, Yáñez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica87(4), 400–407 (2002).
   PubMed Web of Science ®Google Scholar
• Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study. J. Immunother.31(3), 310–312 (2008).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials1(1), 67–74 (2006).
   PubMedGoogle Scholar
• Longo DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst.98(18), 1263–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol.13(1), 140–147 (1995).
   PubMed Web of Science ®Google Scholar
• Inogés S, López-Díaz de Cerio A, Zabalegui N et al. Prolonged idiotypic vaccination against follicular lymphoma. Leuk. Lymphoma50(1), 47–53 (2009).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Rodríguez-Calvillo M, Inogés S et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma47(1), 29–37 (2006).
   PubMed Web of Science ®Google Scholar
• Inogés S, de Cerio AL, Sampol A et al. Stem cell transplant and idiotypic vaccination for B-cell malignancies. Curr. Top. Med. Chem. (2011) (In Press).
   PubMedGoogle Scholar
• Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med.11(9), 986–991 (2005).
   PubMed Web of Science ®Google Scholar
• Inogés S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M. Idiotype vaccines for human B-cell malignancies. Curr. Pharm. Des.16(3), 300–307 (2010).
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J. Clin. Oncol.27(Suppl.), 18s (2009) (Abstract 2).
   Google Scholar
• Schuster SJ, Santos CF, Neelapu SS et al. Vaccination with IgM but not IgG idiotype prolongs remission duration in follicular lymphoma. Blood116(22), (2010) (Abstract 429).
   PubMedGoogle Scholar
• McCormick AA, Kumagai MH, Hanley K et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA96(2), 703–708 (1999).
   PubMed Web of Science ®Google Scholar
• McCormick AA, Reinl SJ, Cameron TI et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J. Immunol. Methods278(1–2), 95–104 (2003).
   PubMed Web of Science ®Google Scholar
• McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study. Proc. Natl Acad. Sci. USA105(29), 10131–10136 (2008).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK et al. Tumor-specific recombinant idiotype immunization after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk. Lymphoma50(1), 37–46 (2009).
   PubMed Web of Science ®Google Scholar
• Levy R. Robertson MJ, Ganjoo K, Leonard JP, Vose J, Denney D. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin’s lymphoma (fNHL). Presented at: 99th Annual Meeting of the American Association for Cancer Research San Diego, CA, USA, 12–16 April, 2008 (Abstract LB-204).
   Google Scholar
• López Díaz de Cerio A, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene26(25), 3594–3602 (2007).
   PubMedGoogle Scholar
• Redfern CH, Guthrie TH, Bessudo A et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J. Clin. Oncol.24(19), 3107–3112 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman A, Neelapu SS, Nichols C et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-t and granulocyte–macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol.27(18), 3036–3043 (2009).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin.58(5), 305–317 (2008).
   PubMed Web of Science ®Google Scholar
• Navarrete MA, Heining-Mikesch K, Schüler F et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood117(5), 1483–1491 (2010).
   PubMedGoogle Scholar